Table 2.
A summary of published clinical trials testing curcumin in patients with pancreatic cancer
| Dhillon et al[47] | Kanai et al[48] | Epelbaum et al[49] | Kanai et al[69] | |
| Sample size | 25 | 21 | 17 | 14 |
| Study design | Phase II | Phase I/II | Phase II | Phase I |
| Study period | 20081 | 2008-2009 | 2004-2006 | 2011-2012 |
| Dose of curcumin | 8 g/d | 8 g/d | 8 g/d | 200 mg/d2 (n = 9) 400 mg/d2 (n = 5) |
| Prior history of chemotherapy | Yes (n = 22) | Yes (n = 21) | None | yes (n = 14) |
| Concomitant use of anticancer drug | No | Yes | Yes | Yes |
| Major toxicity associated with curcumin | None | None | Abdominal discomfort (n = 5) | Abdominal pain (n = 2) |
| Median survival time (mo) | NA | 5.4 | 5 | 4.4 |
1
Publication year;
2
THERACURMIN® was used in this study. NA: Not available.